A Study Comparing Diclofenac Sodium Gel 3% to Solaraze速 Gel 3% in the Treatment of Actinic Keratosis
The objective of this study is to compare the relative efficacy and safety of the test formulation diclofenac sodium gel 3% (Taro Pharmaceuticals Inc.) to the marketed formulation Solaraze速 (diclofenac sodium) Gel 3% (Fougera Pharms) in the treatment of actinic keratosis.

Both the test and reference formulations will also be compared to a placebo formulation to test for superiority.
Actinic Keratosis
DRUG: Diclofenac Sodium Gel 3%|DRUG: Solaraze速 (diclofenac sodium) Gel 3%|DRUG: Vehicle Topical Gel
Bioequivalence, Bioequivalence will be determined by evaluating the proportion of patients in the test and reference groups with 100% clearance of all AK lesions in the treatment area., Study day 90 (30 days after completion of 60 days of treatment)
Superiority to placebo, The superiority of the test and reference gels against the placebo will be tested by the proportion of patients showing 100% clearance of actinic keratosis lesions at Day 90 (30 days after completion of 60 days of treatment)using the modified intent to treat population and last observation carried forward., Study day 90 (30 days after completion of 60 days of treatment)
The objective of this study is to compare the relative efficacy and safety of the test formulation diclofenac sodium gel 3% (Taro Pharmaceuticals Inc.) to the marketed formulation Solaraze速 (diclofenac sodium) Gel 3% (Fougera Pharms) in the treatment of actinic keratosis.

Both the test and reference formulations will also be compared to a placebo formulation to test for superiority.